Compare · CAH vs MEDS
CAH vs MEDS
Side-by-side comparison of Cardinal Health Inc. (CAH) and TRxADE HEALTH Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAH and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CAH is the larger of the two at $58.75B, about 4278.1x MEDS ($13.7M).
- MEDS has been more active in the news (9 items in the past 4 weeks vs 3 for CAH).
- CAH has more recent analyst coverage (25 ratings vs 1 for MEDS).
- Company
- Cardinal Health Inc.
- TRxADE HEALTH Inc.
- Price
- -
- -
- Market cap
- $58.75B
- $13.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 1
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
TRxADE HEALTH Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Latest CAH
- Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
- Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
- SEC Form DEF 14A filed by Cardinal Health Inc.
- SEC Form DEFA14A filed by Cardinal Health Inc.
- Chief Accounting Officer Scherer Mary C. sold $546,473 worth of shares (2,302 units at $237.39), decreasing direct ownership by 45% to 2,811 units (SEC Form 4)
- Chief Executive Officer Hollar Jason M. sold $29,375,516 worth of shares (124,529 units at $235.89), decreasing direct ownership by 40% to 190,603 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M sold $8,274,117 worth of shares (35,000 units at $236.40), decreasing direct ownership by 66% to 18,061 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah sold $1,731,524 worth of shares (7,354 units at $235.45), decreasing direct ownership by 9% to 77,901 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E sold $9,926,140 worth of shares (42,000 units at $236.34), decreasing direct ownership by 67% to 20,495 units (SEC Form 4)
Latest MEDS
- DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
- DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
- DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
- DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
- Datameds AI Files DBAs Datameds SI And Corexa Health SI And Reminds Shareholders Of Record As Of August 7, 2026 Of Dream Bowl Meme Coin I Payment
- These Stocks Roar into October with Fresh Catalysts
- DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
- 4 Explosive Stories Enter the Investor Spotlight
- DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application
- DataMEDS AI To Present At 2026 National Telehealth and Virtual Care Summit